{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:14:25Z","timestamp":1792599265621,"version":"4.5.0"},"reference-count":116,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022274","name":"Daiichi Sankyo Europe GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The clinically important link between LDL cholesterol (LDL\u2009-\u2009C) lowering and cardiovascular (CV) risk reduction is well-established and reflected in the 2019 European Society of Cardiology\/European Atherosclerosis Society guidelines for the management of dyslipidaemia. They recommend a stepwise approach to reaching LDL\u2009-\u2009C goals, beginning with statin monotherapy at the highest tolerated dose. However, real-world data show a large gap between guideline LDL\u2009-\u2009C goal recommendations and their achievement in clinical practice. The treatment paradigm should shift from the concept of high-intensity statins to that of high-intensity, lipid-lowering therapy (LLT), preferably as upfront combination LLT, to overcome the residual CV risk associated with inadequate lipid management.<\/jats:p>\n               <jats:p>A multidisciplinary expert panel convened to propose treatment algorithms to support this treatment approach in patients at high and very high CV risk. The experts completed a questionnaire on the benefits of combination therapy and the role that novel LLTs, including bempedoic acid, might play in future guidelines. The integration of new LLTs into the suggested treatment algorithms for patients at high CV risk, very high CV risk, and those with complete or partial statin intolerance was discussed. Each algorithm considers baseline CV risk and LDL\u2009-\u2009C levels when recommending the initial treatment strategy. This expert consensus endorses the use of statin combination therapy as first-line therapy in patients at high and very high CV risk, and, in some circumstances, in patients with statin intolerance when appropriate. Given recent, compelling evidence, including real-world data, combination therapy as first-line treatment should be considered to help patients achieve their LDL\u2009-\u2009C goals.<\/jats:p>","DOI":"10.1093\/ehjcvp\/pvaf007","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T10:21:41Z","timestamp":1741342901000},"page":"367-379","source":"Crossref","is-referenced-by-count":29,"title":["Expert opinion on the integration of combination therapy into the treatment algorithm for the management of dyslipidaemia: the integration of ezetimibe and bempedoic acid may enhance goal attainment"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9873-0412","authenticated-orcid":false,"given":"Klaus G","family":"Parhofer","sequence":"first","affiliation":[{"name":"Medizinische Klinik und Poliklinik IV\u2014Gro\u00dfhadern, LMU Klinikum , Marchioninistr. 15, Munich 81377 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5970-6353","authenticated-orcid":false,"given":"Carlos","family":"Aguiar","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Unidade Local de Sa\u00fade Lisboa Ocidental, Hospital Santa Cruz , Av. Prof. Dr Reinaldo dos Santos, 2790-134 Carnaxide ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[{"name":"Department of Preventive Cardiology and Lipidology, Medical University of Lodz , Rzgowska 281\/289, Lodz 93-338 ,","place":["Poland"]},{"name":"Department of Cardiology and Adult Congenital Heart Diseases, Polish Mother's Memorial Hospital Research Institute , Rzgowska 281\/289, 93-338 Lodz ,","place":["Poland"]},{"name":"Faculty of Medicine, The John Paul II Catholic University of Lublin, Aleje Rac\u0142awickie 14 , Lublin 20-950 ,","place":["Poland"]},{"name":"Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine , 600\u00a0N. Wolfe St, Carnegie 591, Baltimore, MD 21287 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4677-9756","authenticated-orcid":false,"given":"Heinz","family":"Drexel","sequence":"additional","affiliation":[{"name":"Vorarlberg Institute for Vascular Investigation and Treatment , Carinagasse 47, 6800 Feldkirch ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Gouni-Berthold","sequence":"additional","affiliation":[{"name":"Center for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne , Kerpener Str. 62, Cologne 50937 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leopoldo","family":"P\u00e9rez de Isla","sequence":"additional","affiliation":[{"name":"Cardiology Department, Clinico San Carlos University Hospital, Universidad Complutense de Madrid, Calle del Prof Mart\u00edn Lagos , Madrid 28040 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst","family":"Rietzschel","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, Ghent University Hospital , Corneel Heymanslaan 10, Gent 9000 ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7096-5201","authenticated-orcid":false,"given":"Alberto","family":"Zambon","sequence":"additional","affiliation":[{"name":"Clinica Medica 1, Department of Medicine, University of Padua , Via Giustiniani 2, 35128 Padua ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik K","family":"Ray","sequence":"additional","affiliation":[{"name":"Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, School of Public Health, Imperial College London , 90 Wood Lane, London W12 0BZ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"2025070708270194700_bib1","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","article-title":"Global burden of cardiovascular diseases and risks, 1990\u20132022","volume":"82","author":"Mensah","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025070708270194700_bib2","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","article-title":"Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"403","author":"GBD 2021 Causes of Death Collaborators","year":"2024","journal-title":"Lancet"},{"key":"2025070708270194700_bib3","first-page":"11","article-title":"The heart of the world","volume-title":"Glob Heart","author":"Di Cesare","year":"2024"},{"key":"2025070708270194700_bib4","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"2025070708270194700_bib5","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1161\/CIRCULATIONAHA.106.676890","article-title":"Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications","volume":"116","author":"Tabas","year":"2007","journal-title":"Circulation"},{"key":"2025070708270194700_bib6","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.jacc.2015.02.020","article-title":"Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 \u00d7 2 factorial mendelian randomization study","volume":"65","author":"Ference","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2025070708270194700_bib7","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2025070708270194700_bib8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2025070708270194700_bib9","first-page":"364","article-title":"Association of triglyceride-lowering LPL variants and LDL\u2009-\u2009C-lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2025070708270194700_bib10","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a mendelian randomization analysis","volume":"60","author":"Ference","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2025070708270194700_bib11","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial","volume":"291","author":"Nissen","year":"2004","journal-title":"JAMA"},{"key":"2025070708270194700_bib12","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL\u2009-\u2009C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"2025070708270194700_bib13","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"2025070708270194700_bib14","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"2025070708270194700_bib15","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1093\/eurheartj\/ehx450","article-title":"Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration","volume":"39","author":"Ference","year":"2018","journal-title":"Eur Heart J."},{"key":"2025070708270194700_bib16","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41569-024-01039-5","article-title":"The LDL cumulative exposure hypothesis: evidence and practical applications","volume":"21","author":"Ference","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"2025070708270194700_bib17","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"2025070708270194700_bib18","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.5114\/aoms\/141941","article-title":"PoLA\/CFPiP\/PCS\/PSLD\/PSD\/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021","volume":"17","author":"Banach","year":"2021","journal-title":"Arch Med Sci"},{"key":"2025070708270194700_bib19","volume-title":"Alirocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia","author":"National Institute for Health and Care Excellence","year":"2016"},{"key":"2025070708270194700_bib20","volume-title":"Inclisiran for Treating Primary Hypercholesterolaemia or Mixed Dyslipidaemia","author":"National Institute for Health and Care Excellence","year":"2021"},{"key":"2025070708270194700_bib21","volume-title":"Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia","author":"National Institute for Health and Care Excellence","year":"2016"},{"key":"2025070708270194700_bib22","doi-asserted-by":"crossref","first-page":"100624","DOI":"10.1016\/j.lanepe.2023.100624","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2025070708270194700_bib23","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1161\/CIRCOUTCOMES.122.009787","article-title":"Gaps in guideline-based lipid-lowering therapy for secondary prevention in the United States: a retrospective cohort study of 322\u2005153 patients","volume":"16","author":"Navar","year":"2023","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2025070708270194700_bib24","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/eurjpc\/zwae199","article-title":"Use of combination therapy is associated with improved LDL\u2009-\u2009cholesterol management: 1-year follow-up results from the European observational SANTORINI study","volume":"31","author":"Ray","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2025070708270194700_bib25","first-page":"1","article-title":"Combination therapy in the guidelines: from high-intensity statins to high-intensity lipid-lowering therapies","volume":"1","author":"Masana","year":"2022","journal-title":"Eur Atheroscler J"},{"key":"2025070708270194700_bib26","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/eurheartj\/ehab718","article-title":"Combination lipid-lowering therapy as first-line strategy in very high-risk patients","volume":"43","author":"Ray","year":"2021","journal-title":"Eur Heart J"},{"key":"2025070708270194700_bib27","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/ehjacc\/zuac123","article-title":"Acute LDL\u2009-\u2009C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy","volume":"11","author":"Krychtiuk","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2025070708270194700_bib28","doi-asserted-by":"crossref","first-page":"105499","DOI":"10.1016\/j.phrs.2021.105499","article-title":"Optimal use of lipid-lowering therapy after acute coronary syndromes: a position Paper endorsed by the International Lipid Expert Panel (ILEP)","volume":"166","author":"Banach","year":"2021","journal-title":"Pharmacol Res"},{"key":"2025070708270194700_bib29","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s40265-024-02105-5","article-title":"2024 recommendations on the optimal use of lipid-lowering therapy in established atherosclerotic cardiovascular disease and following acute coronary syndromes: a position paper of the International Lipid Expert Panel (ILEP)","volume":"84","author":"Banach","year":"2024","journal-title":"Drugs"},{"key":"2025070708270194700_bib30","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jama.2022.12138","article-title":"Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"328","author":"Chou","year":"2022","journal-title":"JAMA"},{"key":"2025070708270194700_bib31","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa065994","article-title":"Long-term follow-up of the West of Scotland coronary prevention study","volume":"357","author":"Ford","year":"2007","journal-title":"N Engl J Med"},{"key":"2025070708270194700_bib32","doi-asserted-by":"crossref","first-page":"e2135371","DOI":"10.1001\/jamanetworkopen.2021.35371","article-title":"Trends in use and expenditures for brand-name statins after introduction of generic statins in the US, 2002\u20132018","volume":"4","author":"Lin","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025070708270194700_bib33","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"2025070708270194700_bib34","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","journal-title":"Lancet"},{"key":"2025070708270194700_bib35","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"2025070708270194700_bib36","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists Collaboration","year":"2010","journal-title":"Lancet"},{"key":"2025070708270194700_bib37","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.jacc.2008.08.039","article-title":"Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients","volume":"52","author":"Mills","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2025070708270194700_bib38","first-page":"CD004816","article-title":"Statins for the primary prevention of cardiovascular disease","volume":"2013","author":"Taylor","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"2025070708270194700_bib39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40256-017-0259-7","article-title":"Management of Statin intolerance in 2018: still more questions than answers","volume":"18","author":"Toth","year":"2018","journal-title":"Am J Cardiovasc Drugs"},{"key":"2025070708270194700_bib40","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.amjcard.2005.09.134","article-title":"Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the cholesterol and pharmacogenetics (CAP) study","volume":"97","author":"Simon","year":"2006","journal-title":"Am J Cardiol"},{"key":"2025070708270194700_bib41","first-page":"301","article-title":"LDL cholesterol reduction variability with different types and doses of statins in monotherapy or combined with Ezetimibe. Results from the Spanish Arteriosclerosis Society Dyslipidaemia Registry","volume-title":"Cardiovasc Drugs Ther","author":"Climent","year":"2022"},{"key":"2025070708270194700_bib42","first-page":"212","article-title":"Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER","volume-title":"Eur Heart J Cardiovasc Pharmacothe","author":"Karlson","year":"2016"},{"key":"2025070708270194700_bib43","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jacl.2022.05.068","article-title":"NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient","volume":"16","author":"Cheeley","year":"2022","journal-title":"J Clin Lipidol"},{"key":"2025070708270194700_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2015.49807","article-title":"Statin intolerance\u2014an attempt at a unified definition. Position paper from an International Lipid Expert Panel","volume":"11","author":"Banach","year":"2015","journal-title":"Arch Med Sci"},{"key":"2025070708270194700_bib45","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.jacc.2017.07.752","article-title":"Optimizing cholesterol treatment in patients with muscle complaints","volume":"70","author":"Rosenson","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2025070708270194700_bib46","doi-asserted-by":"crossref","first-page":"e010376","DOI":"10.1161\/JAHA.118.010376","article-title":"Adherence to statin therapy among US adults between 2007 and 2014","volume":"8","author":"Colantonio","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2025070708270194700_bib47","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.mayocp.2018.01.011","article-title":"Reinitiation of Statin therapy after discontinuation: a meta-analysis","volume":"93","author":"Ofori-Asenso","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"2025070708270194700_bib48","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/jcsm.12960","article-title":"Step-by-step diagnosis and management of the nocebo\/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)","volume":"13","author":"Penson","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2025070708270194700_bib49","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1093\/eurheartj\/eht295","article-title":"Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences","volume":"34","author":"Chowdhury","year":"2013","journal-title":"Eur Heart J"},{"key":"2025070708270194700_bib50","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ahj.2020.10.060","article-title":"Rationale and design of the CLEAR-outcomes trial: evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance","volume":"235","author":"Nicholls","year":"2021","journal-title":"Am Heart J"},{"key":"2025070708270194700_bib51","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2174\/156800605774962086","article-title":"Cholesterol absorption blockade with ezetimibe","volume":"5","author":"Toth","year":"2005","journal-title":"Curr Drug Targets Cardiovasc Haematol Disord"},{"key":"2025070708270194700_bib52","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0195-668X(02)00807-2","article-title":"Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia","volume":"24","author":"Knopp","year":"2003","journal-title":"Eur Heart J"},{"key":"2025070708270194700_bib53","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.amjcard.2006.10.022","article-title":"Efficacy and safety of rosuvastatin 40\u00a0mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study)","volume":"99","author":"Ballantyne","year":"2007","journal-title":"Am J Cardiol"},{"key":"2025070708270194700_bib54","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to Statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"2025070708270194700_bib55","doi-asserted-by":"crossref","first-page":"9815016","DOI":"10.1155\/2020\/9815016","article-title":"Ezetimibe and improving cardiovascular outcomes: current evidence and perspectives","volume":"2020","author":"Pradhan","year":"2020","journal-title":"Cardiol Res Pract"},{"key":"2025070708270194700_bib56","doi-asserted-by":"crossref","first-page":"e000134","DOI":"10.1136\/bmjmed-2022-000134","article-title":"Safety of ezetimibe in lipid-lowering treatment: systematic review and meta-analysis of randomised controlled trials and cohort studies","volume":"1","author":"Wang","year":"2022","journal-title":"BMJ Med"},{"key":"2025070708270194700_bib57","author":"US Food and Drug Administration","year":"2017","journal-title":"2017 First Generic Drug Approvals"},{"key":"2025070708270194700_bib58","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL\u2009-\u2009C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Comm"},{"key":"2025070708270194700_bib59","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1016\/j.jacl.2021.09.036","article-title":"Safety and efficacy of Bempedoic acid in statin-intolerant patients","volume":"16","author":"Buda","year":"2022","journal-title":"J Clin Lipidol"},{"key":"2025070708270194700_bib60","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"key":"2025070708270194700_bib61","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"key":"2025070708270194700_bib62","doi-asserted-by":"crossref","first-page":"e011662","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance","volume":"8","author":"Laufs","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2025070708270194700_bib63","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Eng J Med"},{"key":"2025070708270194700_bib64","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s12933-023-02022-z","article-title":"Safety and efficacy of bempedoic acid: a systematic review and meta-analysis of randomised controlled trials","volume":"22","author":"De Filippo","year":"2023","journal-title":"Cardiovasc Diabet"},{"key":"2025070708270194700_bib65","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jacl.2020.08.009","article-title":"Bempedoic acid safety analysis: pooled data from four phase 3 clinical trials","volume":"14","author":"Bays","year":"2020","journal-title":"J Clin Lipidol"},{"key":"2025070708270194700_bib66","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"2025070708270194700_bib67","volume-title":"Nustendi: Summary of Product Characteristics. EMA","author":"European Medicine Agency","year":"2024"},{"key":"2025070708270194700_bib68","volume-title":"Nilemdo: Summary of Product Characteristics","author":"European Medicine Agency","year":"2024"},{"key":"2025070708270194700_bib69","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.pcad.2023.03.001","article-title":"Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP)","volume":"79","author":"Banach","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"key":"2025070708270194700_bib70","first-page":"41","article-title":"Bempedoic acid: new evidence and recommendations on use","volume":"35","author":"Paponja","year":"2024","journal-title":"Curr Opinion Lipidol"},{"key":"2025070708270194700_bib71","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the management of chronic coronary syndromes: developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) endorsed by the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"2025070708270194700_bib72","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1093\/eurheartj\/ehae179","article-title":"2024 ESC guidelines for the management of peripheral arterial and aortic diseases: developed by the task force on the management of peripheral arterial and aortic diseases of the European Society of Cardiology (ESC) endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN), and the European Society of Vascular Medicine (ESVM)","volume":"45","author":"Mazzolai","year":"2024","journal-title":"Eur Heart J"},{"key":"2025070708270194700_bib73","volume-title":"Bempedoic Acid","author":"Adis Insight","year":"2025."},{"key":"2025070708270194700_bib74","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41392-023-01690-3","article-title":"Targeting proprotein convertase subtilisin\/kexin type 9 (PCSK9): from bench to bedside","volume":"9","author":"Bao","year":"2024","journal-title":"Signal Transducti Target Ther"},{"key":"2025070708270194700_bib75","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2025070708270194700_bib76","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"2025070708270194700_bib77","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial","volume":"327","author":"R\u00e4ber","year":"2022","journal-title":"JAMA"},{"key":"2025070708270194700_bib78","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.jacc.2023.08.019","article-title":"Concomitant coronary atheroma regression and stabilization in response to lipid-lowering therapy","volume":"82","author":"Biccir\u00e8","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025070708270194700_bib79","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025070708270194700_bib80","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"2025070708270194700_bib81","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3390\/ph16040577","article-title":"Inclisiran, low-density lipoprotein cholesterol and lipoprotein (a)","volume":"16","author":"Katsiki","year":"2023","journal-title":"Pharmaceuticals"},{"key":"2025070708270194700_bib82","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2020","journal-title":"Eur J Prevent Cardiol"},{"key":"2025070708270194700_bib83","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.cjca.2019.04.008","article-title":"Treatment and low-density lipoprotein cholesterol management in patients diagnosed with clinical atherosclerotic cardiovascular disease in Alberta","volume":"35","author":"Chen","year":"2019","journal-title":"Can J Cardiol"},{"key":"2025070708270194700_bib84","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.cjca.2016.07.510","article-title":"2016 Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of Cardiovascular disease in the adult","volume":"32","author":"Anderson","year":"2016","journal-title":"Can J Cardiol"},{"key":"2025070708270194700_bib85","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2021.1810","article-title":"Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US","volume":"6","author":"Cannon","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2025070708270194700_bib86","doi-asserted-by":"crossref","first-page":"212","DOI":"10.5935\/abc.20130062","article-title":"Evidence-based therapy prescription in high-cardiovascular risk patients: the REACT study","volume":"100","author":"Berwanger","year":"2013","journal-title":"Arq Bras Cardiol"},{"key":"2025070708270194700_bib87","doi-asserted-by":"crossref","first-page":"100665","DOI":"10.1016\/j.lanepe.2023.100665","article-title":"Optimal implementation of the 2019 ESC\/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI study","volume":"31","author":"Brandts","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2025070708270194700_bib88","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11886-020-01326-w","article-title":"Reasons why combination therapy should be the new standard of care to achieve the LDL\u2009-\u2009cholesterol targets: lipid-lowering combination therapy","volume":"22","author":"Masana","year":"2020","journal-title":"Curr Cardiol Rep"},{"key":"2025070708270194700_bib89","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.amjcard.2009.08.651","article-title":"Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER)","volume":"105","author":"Nicholls","year":"2010","journal-title":"Am J Cardiol"},{"key":"2025070708270194700_bib90","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/eurjpc\/zwae028","article-title":"Beyond early LDL cholesterol lowering to prevent coronary atherosclerosis in familial hypercholesterolaemia","volume":"31","author":"Ibrahim","year":"2024","journal-title":"Eur J Prevent Cardiol"},{"key":"2025070708270194700_bib91","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1093\/eurheartj\/ehae576","article-title":"Intensive early and sustained lowering of non\u2014high-density lipoprotein cholesterol after myocardial infarction and prognosis: the SWEDEHEART registry","volume":"45","author":"Schubert","year":"2024","journal-title":"Eur Heart J"},{"key":"2025070708270194700_bib92","doi-asserted-by":"crossref","first-page":"106738","DOI":"10.1016\/j.phrs.2023.106738","article-title":"Lipid lowering combination therapy: from prevention to atherosclerosis plaque treatment","volume":"190","author":"Masana","year":"2023","journal-title":"Pharmacol Res"},{"key":"2025070708270194700_bib93","doi-asserted-by":"crossref","first-page":"e0276898","DOI":"10.1371\/journal.pone.0276898","article-title":"Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular risk","volume":"17","author":"Katzmann","year":"2022","journal-title":"PLoS One"},{"key":"2025070708270194700_bib94","doi-asserted-by":"crossref","first-page":"e030414","DOI":"10.1161\/JAHA.123.030414","article-title":"Intensive statin therapy versus upfront combination therapy of Statin and Ezetimibe in patients with acute coronary syndrome: a propensity score matching analysis based on the PL-ACS data","volume":"12","author":"Lewek","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2025070708270194700_bib95","first-page":"1429","article-title":"2022: the year in cardiovascular disease\u2014the year of upfront lipid lowering combination therapy","volume":"18","author":"Banach","year":"2022","journal-title":"Arch Med Sci"},{"key":"2025070708270194700_bib96","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2021.03.039","article-title":"Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: a statement from a European Atherosclerosis Society Task Force","volume":"325","author":"Averna","year":"2021","journal-title":"Atherosclerosis"},{"key":"2025070708270194700_bib97","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1093\/eurjpc\/zwac214","article-title":"Projected impact of treatment intensification with statin, ezetimibe, and statin plus ezetimibe fixed-dose combination on MACE across six countries","volume":"29","author":"Farnier","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2025070708270194700_bib98","article-title":"Combination therapy with Oral Bempedoic Acid to reach LDL\u2009-\u2009cholesterol targets (COBALT)\u2014a real-world secondary prevention setting study","author":"German Clinical Trials Register","year":"2025"},{"key":"2025070708270194700_bib99","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1080\/00325481.2022.2117498","article-title":"LDL\u2009-\u2009C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals","volume":"134","author":"Underberg","year":"2022","journal-title":"Postgrad Med"},{"key":"2025070708270194700_bib100","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jacl.2013.09.009","article-title":"Therapeutic practice patterns related to statin potency and ezetimibe\/simvastatin combination therapies in lowering LDL\u2009-\u2009C in patients with high-risk cardiovascular disease","volume":"8","author":"Toth","year":"2014","journal-title":"J Clin Lipidol"},{"key":"2025070708270194700_bib101","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12872-016-0283-6","article-title":"Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction","volume":"16","author":"Halvorsen","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"key":"2025070708270194700_bib102","doi-asserted-by":"crossref","first-page":"359","DOI":"10.33963\/KP.a2023.0045","article-title":"Dyslipidemia treatment and attainment of LDL\u2009-\u2009cholesterol treatment goals in patients participating in the Managed Care for Acute Myocardial Infarction Survivors program","volume":"81","author":"Nowowiejska-Wiewi\u00f3ra","year":"2023","journal-title":"Pol Heart J"},{"key":"2025070708270194700_bib103","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s12933-022-01684-5","article-title":"Personalized management of dyslipidemias in patients with diabetes: it is time for a new approach (2022)","volume":"21","author":"Banach","year":"2022","journal-title":"Cardiovas Diabetol"},{"key":"2025070708270194700_bib104","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/S0735-1097(24)03709-4","article-title":"Efficacy of triple combination lipid lowering therapy in patients with acute coronary syndrome","volume":"83","author":"Mahajan","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025070708270194700_bib105","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.atherosclerosis.2020.12.023","article-title":"Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: a randomized clinical trial","volume":"320","author":"Rubino","year":"2021","journal-title":"Atherosclerosis"},{"key":"2025070708270194700_bib106","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/ehjcvp\/pvz079","article-title":"An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: barriers to be overcome","volume":"6","author":"Drexel","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025070708270194700_bib107","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1177\/2374373520948400","article-title":"Does your patient understand their treatment plan? Factors affecting patient understanding of their medical care treatment plan in the inpatient setting","volume":"7","author":"Toole","year":"2020","journal-title":"J Patient Exp"},{"key":"2025070708270194700_bib108","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0140-6736(18)32818-6","article-title":"Visualization of asymptomatic atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA): a pragmatic, open-label, randomised controlled trial","volume":"393","author":"N\u00e4slund","year":"2019","journal-title":"Lancet"},{"key":"2025070708270194700_bib109","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.conctc.2016.10.002","article-title":"Customized care: an intervention to improve communication and health outcomes in multimorbidity","volume":"4","author":"Wittink","year":"2016","journal-title":"Contemp Clin Trials Commun"},{"key":"2025070708270194700_bib110","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1007\/s13311-018-0670-z","article-title":"Statin-associated muscle disease: advances in diagnosis and management","volume":"15","author":"Taylor","year":"2018","journal-title":"Neurotherapeutics"},{"key":"2025070708270194700_bib111","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"2025070708270194700_bib112","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.repc.2014.01.013","article-title":"The impact of dosing frequency on medication adherence in chronic cardiovascular disease: systematic review and meta-analysis","volume":"33","author":"Caldeira","year":"2014","journal-title":"Rev Port Cardiol"},{"key":"2025070708270194700_bib113","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s11883-023-01142-x","article-title":"Fixed combination for the treatment of dyslipidaemia","volume":"25","author":"Ferri","year":"2023","journal-title":"Curr Atheroscler Rep"},{"key":"2025070708270194700_bib114","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/clc.23988","article-title":"Addressing current challenges in optimization of lipid management following an ACS event: outcomes of the ACS EuroPath III initiative","volume":"46","author":"Catapano","year":"2023","journal-title":"Clin Cardiol"},{"key":"2025070708270194700_bib115","doi-asserted-by":"publisher","first-page":"212534","DOI":"10.7573\/dic.212534","article-title":"Adding ezetimibe to statin therapy: latest evidence and clinical implications","volume":"7","author":"Vavlukis","year":"2018","journal-title":"Drugs Context"},{"key":"2025070708270194700_bib116","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.15420\/ecr.2023.14","article-title":"Proprotein convertase subtilisin\/kexin Type 9 inhibition: the big step forward in lipid control","volume":"18","author":"Rikhi","year":"2023","journal-title":"Eur Cardiol"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvaf007\/62310158\/pvaf007.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/4\/367\/62310158\/pvaf007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/4\/367\/62310158\/pvaf007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T12:27:23Z","timestamp":1751891243000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/11\/4\/367\/8058873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":116,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,3,6]]},"published-print":{"date-parts":[[2025,7,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvaf007","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,3,6]]}}}